Wall Street analysts expect that PerkinElmer, Inc. (NYSE:PKI) will announce earnings per share (EPS) of $0.94 for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for PerkinElmer’s earnings. The lowest EPS estimate is $0.92 and the highest is $0.95. PerkinElmer reported earnings per share of $0.83 during the same quarter last year, which suggests a positive year-over-year growth rate of 13.3%. The business is expected to report its next quarterly earnings results on Thursday, February 1st.

According to Zacks, analysts expect that PerkinElmer will report full-year earnings of $2.89 per share for the current year, with EPS estimates ranging from $2.87 to $2.92. For the next fiscal year, analysts forecast that the company will report earnings of $3.16 per share, with EPS estimates ranging from $3.13 to $3.20. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover PerkinElmer.

PKI has been the subject of several analyst reports. Robert W. Baird restated a “buy” rating and set a $72.00 target price on shares of PerkinElmer in a research report on Friday, October 20th. Citigroup boosted their target price on PerkinElmer from $67.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, August 7th. Piper Jaffray Companies restated a “buy” rating and set a $81.00 target price on shares of PerkinElmer in a research report on Friday, August 4th. Cowen reiterated a “hold” rating and issued a $70.00 price objective on shares of PerkinElmer in a research report on Friday, September 1st. Finally, Jefferies Group reiterated a “hold” rating and issued a $70.00 price objective on shares of PerkinElmer in a research report on Friday, October 20th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $68.64.

In other news, Director Nicholas A. Lopardo sold 24,050 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $70.72, for a total transaction of $1,700,816.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Peter Barrett sold 7,071 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $71.07, for a total value of $502,535.97. Following the sale, the director now owns 26,271 shares in the company, valued at approximately $1,867,079.97. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio raised its stake in shares of PerkinElmer by 4.4% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 49,515 shares of the medical research company’s stock worth $3,415,000 after purchasing an additional 2,098 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of PerkinElmer during the 3rd quarter worth approximately $297,000. Neuberger Berman Group LLC raised its stake in shares of PerkinElmer by 3.1% during the 3rd quarter. Neuberger Berman Group LLC now owns 53,664 shares of the medical research company’s stock worth $3,701,000 after purchasing an additional 1,634 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of PerkinElmer by 1.9% during the 3rd quarter. California Public Employees Retirement System now owns 280,665 shares of the medical research company’s stock worth $19,357,000 after purchasing an additional 5,165 shares in the last quarter. Finally, Chevy Chase Trust Holdings Inc. raised its stake in shares of PerkinElmer by 1.4% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 96,127 shares of the medical research company’s stock worth $6,630,000 after purchasing an additional 1,329 shares in the last quarter. Institutional investors own 91.66% of the company’s stock.

PerkinElmer (NYSE:PKI) traded down $0.60 during trading on Friday, hitting $73.08. The stock had a trading volume of 163,433 shares, compared to its average volume of 632,139. The firm has a market cap of $8,070.00, a price-to-earnings ratio of 26.55, a P/E/G ratio of 2.21 and a beta of 0.77. PerkinElmer has a 52 week low of $50.51 and a 52 week high of $74.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.59 and a quick ratio of 2.09.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 9th. Shareholders of record on Friday, January 19th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.38%. The ex-dividend date of this dividend is Thursday, January 18th. PerkinElmer’s payout ratio is 12.67%.

WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/01/zacks-brokerages-expect-perkinelmer-inc-pki-to-announce-0-94-earnings-per-share.html.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Get a free copy of the Zacks research report on PerkinElmer (PKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.